NYSE:TDOCTeladoc Health Stock Price, Forecast & News

$146.66

+7.56 (+5.43 %)

(As of 04/9/2020 04:00 PM ET)

Add

Compare

Today's Range

$136.41

Now: $146.66▼

$148.25

50-Day Range

$113.54

MA: $136.41▼

$167.44

52-Week Range

$48.57

Now: $146.66▼

$176.40

Volume2.54 million shs

Average Volume2.87 million shs

Market Capitalization$10.71 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.48

Teladoc Health, Inc. provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers, health plans, health systems, and other entities in approximately 100 countries worldwide. Teladoc Health, Inc. has a collaboration with Cincinnati Children's Hospital Medical Center to develop a consumer pediatric telehealth platform. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was founded in 2002 and is headquartered in Purchase, New York.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Teladoc Health has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 12 buy ratings, 12 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $123.32, Teladoc Health has a potential downside of 15.9% from its current price of $146.66.
Amount of Analyst Coverage
Teladoc Health has been the subject of 20 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Teladoc Health has received 530 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Teladoc Health has received 482 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Teladoc Health has received 52.37% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Teladoc Health and other stocks. Vote “Outperform” if you believe TDOC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TDOC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Teladoc Health does not currently pay a dividend.
Dividend Growth
Teladoc Health does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Teladoc Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.95% of the stock of Teladoc Health is held by insiders.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Teladoc Health are expected to decrease by -35.40% in the coming year, from ($1.13) to ($0.73) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Teladoc Health is -106.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Teladoc Health is -106.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Teladoc Health has a P/B Ratio of 10.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.97 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Offices & clinics of medical doctors

Sub-IndustryN/A

SectorMedical

Current SymbolNYSE:TDOC

Previous Symbol

CUSIPN/A

CIK1477449

Webhttp://www.teladoc.com/

Phone203-635-2002

Debt

Debt-to-Equity Ratio0.43

Current Ratio6.52

Quick Ratio6.52

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$553.31 million

Price / Sales19.35

Cash FlowN/A

Price / Cash FlowN/A

Book Value$14.01 per share

Price / Book10.47

Profitability

EPS (Most Recent Fiscal Year)($1.49)

Net Income$-98,860,000.00

Net Margins-17.87%

Return on Equity-10.65%

Return on Assets-6.79%

Miscellaneous

Employees2,400

Outstanding Shares73,008,000

Market Cap$10.71 billion

Next Earnings Date5/5/2020 (Estimated)

OptionableOptionable

Receive TDOC News and Ratings via Email

Sign-up to receive the latest news and ratings for TDOC and its competitors with MarketBeat's FREE daily newsletter.

Teladoc Health (NYSE:TDOC) Frequently Asked Questions

How has Teladoc Health's stock been impacted by COVID-19 (Coronavirus)?

Teladoc Health's stock was trading at $137.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TDOC stock has increased by 6.7% and is now trading at $146.66. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Teladoc Health?

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last year. There are currently 12 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Teladoc Health.

When is Teladoc Health's next earnings date?

Teladoc Health is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Teladoc Health.

How were Teladoc Health's earnings last quarter?

Teladoc Health Inc (NYSE:TDOC) posted its quarterly earnings data on Wednesday, February, 26th. The health services provider reported ($0.26) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.33) by $0.07. The health services provider had revenue of $156.49 million for the quarter, compared to analysts' expectations of $153.79 million. Teladoc Health had a negative return on equity of 10.65% and a negative net margin of 17.87%. View Teladoc Health's earnings history.

What guidance has Teladoc Health issued on next quarter's earnings?

Teladoc Health issued an update on its FY20 earnings guidance on Wednesday, February, 26th. The company provided earnings per share guidance of (1.19-1.06) for the period, compared to the Thomson Reuters consensus earnings per share estimate of ($1.16). The company issued revenue guidance of $695-710 million, compared to the consensus revenue estimate of $689.24 million.

What price target have analysts set for TDOC?

24 equities research analysts have issued 12-month price objectives for Teladoc Health's shares. Their forecasts range from $75.00 to $179.00. On average, they expect Teladoc Health's stock price to reach $123.32 in the next twelve months. This suggests that the stock has a possible downside of 15.9%. View analysts' price targets for Teladoc Health.

What are Wall Street analysts saying about Teladoc Health stock?

Here are some recent quotes from research analysts about Teladoc Health stock:

1. According to Zacks Investment Research, "Teladoc Health’s shares have outperformed the industry year to date. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. The company has started international expansion with the acquisition of Advance Medical in 2018, which was built on its buyout of Best Doctors in 2017. In 2018, the company launched Global Care Services which caters to its international business. It has been witnessing continued growth in revenues over the quarters, driven by an increase in membership and patient visits. However, the company has incurred significant loss and has been unable to generate cash from operations. Its struggle may continue in the coming quarters. Its high debt level and interest expense weigh on margins." (11/27/2019)
2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on TDOC shares. Our price target is $70. After the close on Tuesday, April 30, TDOC reported 1Q18 results that were in line with our estimates and reaffirmed its 2019 guidance. Organic revenue growth was 23% compared with 31% in 4Q18. Importantly, the company indicated that it has expanded its relationship with UnitedHealthcare (UNH – Overweight). The company reiterated that it should be able to maintain organic revenue growth in the 20-30% range next year. The company remains optimistic on Medicare Advantage (MA) plans, but expects more ratable adoption over time. On the surface, TDOC is executing nicely on its virtual health strategy." (4/30/2019)

Has Teladoc Health been receiving favorable news coverage?

News coverage about TDOC stock has trended very negative on Thursday, InfoTrie reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Teladoc Health earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media headlines about the health services provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutTeladoc Health.

Who are some of Teladoc Health's key competitors?

Some companies that are related to Teladoc Health include Edwards Lifesciences (EW), HCA Healthcare (HCA), Siemens Healthineers (SHL), RESMED/IDR UNRESTR (RMD), Centene (CNC), LONZA GRP AG/ADR (LZAGY), COLOPLAST A/S/ADR (CLPBY), Actelion (ALIOF), ASTELLAS PHARMA/ADR (ALPMY), TERUMO CORP/ADR (TRUMY), ESSILOR INTL S/S (ESLOY), Takeda Pharmaceutical (TKPYY), DexCom (DXCM), McKesson (MCK) and FRESENIUS SE &/S (FSNUY).

What other stocks do shareholders of Teladoc Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teladoc Health investors own include NVIDIA (NVDA), Alibaba Group (BABA), Shopify (SHOP), Netflix (NFLX), Walt Disney (DIS), Square (SQ), Advanced Micro Devices (AMD), Trade Desk (TTD), Twilio (TWLO) and Paypal (PYPL).

Who are Teladoc Health's key executives?

Teladoc Health's management team includes the following people:

Mr. Jason Nathanial Gorevic, CEO & Director (Age 47)
Mr. Peter A. McClennen, Pres & Interim COO (Age 50)
Mr. Adam Christian Vandervoort, Chief Legal Officer & Sec. (Age 44)
Ms. Stephany Verstraete, Chief Marketing Officer (Age 50)
Dr. George Byron Brooks BS EE, M.D., Co-Founder

When did Teladoc Health IPO?

(TDOC) raised $112 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 7,000,000 shares at $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Teladoc Health's stock symbol?

Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."

Who are Teladoc Health's major shareholders?

Teladoc Health's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Polaris Greystone Financial Group LLC (0.03%), Gradient Investments LLC (0.02%), Harbour Capital Advisors LLC (0.00%), Global Trust Asset Management LLC (0.00%) and PrairieView Partners LLC (0.00%). Company insiders that own Teladoc Health stock include Adam C Vandervoort, Andrew Turitz, Gabriel R Cappucci, Jason N Gorevic, Lewis Levy, Mark Hirschhorn, Michael Goldstein, Michelle Bucaria, Peter A Mcclennen and Stephany Verstraete. View institutional ownership trends for Teladoc Health.

Which major investors are selling Teladoc Health stock?

TDOC stock was sold by a variety of institutional investors in the last quarter, including Gradient Investments LLC. Company insiders that have sold Teladoc Health company stock in the last year include Adam C Vandervoort, Andrew Turitz, Gabriel R Cappucci, Jason N Gorevic, Lewis Levy, and Peter A Mcclennen. View insider buying and selling activity for Teladoc Health.

Which major investors are buying Teladoc Health stock?

TDOC stock was bought by a variety of institutional investors in the last quarter, including Polaris Greystone Financial Group LLC, Harbour Capital Advisors LLC, Global Trust Asset Management LLC, and PrairieView Partners LLC. View insider buying and selling activity for Teladoc Health.

How do I buy shares of Teladoc Health?

Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teladoc Health's stock price today?

One share of TDOC stock can currently be purchased for approximately $146.66.

How big of a company is Teladoc Health?

Teladoc Health has a market capitalization of $10.71 billion and generates $553.31 million in revenue each year. The health services provider earns $-98,860,000.00 in net income (profit) each year or ($1.49) on an earnings per share basis. Teladoc Health employs 2,400 workers across the globe. View additional information about Teladoc Health.

What is Teladoc Health's official website?

The official website for Teladoc Health is http://www.teladoc.com/.

How can I contact Teladoc Health?

Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]

This page was last updated on 4/9/2020 by MarketBeat.com Staff

Featured Article: Book Value Per Share in Stock Trading